FTO and chronic myelogenous leukemia, BCR-ABL1 positive: To pursue the clinical relevance of FTO-induced m6A demethylation, we established nilotinib resistance in primary cells from both an AML and CML patient, respectively, by treating them with increasing concentrations of nilotinib till they could grow in 1 μM nilotinib-containing medium.